Finnish Pharma Company Has Been Granted A Patent for a Covid Nasal Spray, Guess What It Contains...
A coronavirus drug developed by Therapeutica Borealis, a pharmaceutical firm in Turku, has been granted a patent by the United States Patent and Trademark Office (USPTO). The nasal spray contains hydroxychloroquine and ivermectin, among other ingredients.
Earlier in May, the company said it had received approval for a patent application, based on which it expected a final patent this month.
“The final patent is an important milestone for us on our way to the market. Our next goal is to find an established pharmaceutical industry company with an international business scale,” says Professor Kalervo Väänänen, one of the three inventors and founders of Therapeutica Borealis, in a press release on Monday. Väänänen is a cell biologist and former rector of the University of Turku.
Our latest stories...